The human tumor microbiome is composed of tumor type–specific intracellular bacteria

Deborah Nejman(Weizmann Institute of Science), Ilana Livyatan(Weizmann Institute of Science), Garold Fuks(Weizmann Institute of Science), Nancy Gavert(Weizmann Institute of Science), Yaara Zwang(Weizmann Institute of Science), Leore T. Geller(Weizmann Institute of Science), Aviva Rotter-Maskowitz(Weizmann Institute of Science), Roi Weiser(Tel Aviv University), Giuseppe Mallel(Weizmann Institute of Science), Elinor Gigi(Weizmann Institute of Science), Arnon Meltser(Weizmann Institute of Science), Gavin M. Douglas(Dalhousie University), Iris Kamer(Sheba Medical Center), Vancheswaran Gopalakrishnan(The University of Texas MD Anderson Cancer Center), Tali Dadosh(Weizmann Institute of Science), Smadar Levin‐Zaidman(Weizmann Institute of Science), Sofia Avnet(Istituto Ortopedico Rizzoli), Tehila Atlan(Jerusalem College of Technology), Zachary A. Cooper(AstraZeneca (Japan)), Reetakshi Arora(The University of Texas MD Anderson Cancer Center), Alexandria P. Cogdill(The University of Texas MD Anderson Cancer Center), Md Abdul Wadud Khan(The University of Texas MD Anderson Cancer Center), Gabriel O Ologun(The University of Texas MD Anderson Cancer Center), Yuval Bussi(Weizmann Institute of Science), Adina Weinberger(Weizmann Institute of Science), Maya Lotan‐Pompan(Weizmann Institute of Science), Ofra Golani(Weizmann Institute of Science), Gili Perry(Sheba Medical Center), Merav Rokah(Sheba Medical Center), Keren Bahar‐Shany(Sheba Medical Center), Elisa A. Rozeman(Oncode Institute), Christian U. Blank(Oncode Institute), Anat Ronai(Rambam Health Care Campus), Ron Shaoul(Rambam Health Care Campus), Amnon Amit(Technion – Israel Institute of Technology), Tatiana Dorfman(Rambam Health Care Campus), Ran Kremer(Rambam Health Care Campus), Zvi R. Cohen(Tel Aviv University), Sagi Harnof(Tel Aviv University), Tali Siegal(Rabin Medical Center), Einav Yehuda‐Shnaidman(Maccabi Healthcare Services), Einav Nili Gal‐Yam(Sheba Medical Center), Hagit Shapira(Maccabi Healthcare Services), Nicola Baldini(Istituto Ortopedico Rizzoli), Morgan G. I. Langille(Dalhousie University), Alon Ben‐Nun(Tel Aviv University), Bella Kaufman(Tel Aviv University), Aviram Nissan(Sheba Medical Center), Talia Golan(Tel Aviv University), Maya Dadiani(Sheba Medical Center), Keren Levanon(Tel Aviv University), Jair Bar(Tel Aviv University), Shlomit Yust‐Katz(Tel Aviv University), Iris Barshack(Tel Aviv University), Daniel S. Peeper(The Netherlands Cancer Institute), Dan J. Raz(City Of Hope National Medical Center), Eran Segal(Weizmann Institute of Science), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Judith Sandbank(Maccabi Healthcare Services), Noam Shental(Open University of Israel), Ravid Straussman(Weizmann Institute of Science)
Science
May 28, 2020
Cited by 2,358Open Access
Full Text

Abstract

Bacteria were first detected in human tumors more than 100 years ago, but the characterization of the tumor microbiome has remained challenging because of its low biomass. We undertook a comprehensive analysis of the tumor microbiome, studying 1526 tumors and their adjacent normal tissues across seven cancer types, including breast, lung, ovary, pancreas, melanoma, bone, and brain tumors. We found that each tumor type has a distinct microbiome composition and that breast cancer has a particularly rich and diverse microbiome. The intratumor bacteria are mostly intracellular and are present in both cancer and immune cells. We also noted correlations between intratumor bacteria or their predicted functions with tumor types and subtypes, patients' smoking status, and the response to immunotherapy.


Related Papers

No related papers found

Powered by citation graph analysis